AP NEWS

DermTech Announces Addition of Stevan Knezevich, MD PhD to Scientific Advisory Board

November 28, 2018

LA JOLLA, Calif.--(BUSINESS WIRE)--Nov 28, 2018--DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the appointment of Dr. Stevan Knezevich to its Scientific Advisory Board. Dr. Knezevich is Board Certified in Dermatopathology, Anatomic Pathology and Clinical Pathology. He is a leader in the field of dermatopathology with a PhD in Pathology and Laboratory Medicine from the University of Vancouver, B.C., and an MD from the University of Toronto. Dr. Knezevich completed his Pathology Residency and Surgical Fellowship at Barnes-Jewish Hospital, and his Dermatopathology Fellowship at Stanford. Dr. Knezevich is a very well published author of numerous articles including on skin pathology interpretation and accuracy, specifically in the area of melanocytic lesions.

“We are excited to have Dr. Knezevich join DermTech’s Scientific Advisory Board to provide guidance on our melanoma products that help clinicians with biopsy decisions and non-invasive efforts to rule out melanoma more effectively. Dr. Knezevich played an integral part in recent landmark studies on the performance of dermatopathologists interpreting melanocytic lesions,” said Dr. Burkhard Jansen, DermTech’s Chief Medical Officer. “The performance of dermatopathology, the current care standard for ruling out melanoma, is hampered by the inherent limitations and subjectivity of image recognition. Even the best dermatopathologist cannot see and describe early molecular changes that do not have morphological correlates yet. Additional tools are needed to reduce subjectivity and improve pigmented lesion management and patient care,“ added Dr. Knezevich.

About DermTech

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181128005161/en/

CONTACT: DermTech, Inc.

Sarah Dion, MBA

VP, Sales and Marketing

(858) 450-4222

sdion@dermtech.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH GENETICS ONCOLOGY OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE

SOURCE: DermTech, Inc.

Copyright Business Wire 2018.

PUB: 11/28/2018 08:00 AM/DISC: 11/28/2018 08:01 AM

http://www.businesswire.com/news/home/20181128005161/en

AP RADIO
Update hourly